APEPTICO

Focus: APEPTICO is a Vienna-based biotechnology company focused on the development and commercialization of peptide-based drugs for high unmet medical needs. The company operates at a pre-revenue or early-stage biotech scale with a lean pipeline concentrated in critical care indications.

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About APEPTICO

AI assessmentNot Hiring

No open roles listed right now. Follow APEPTICO to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

3 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

AP-301

PGD Primary Graft Dysfunction

Phase 2

Clinical Trials (1)

NCT02095626Study in Intensive Care Patients Regarding the Effect of Inhaled AP-301 After Primary Graft Dysfunction After Lung Transplantation

Phase 2

Help build intelligence for APEPTICO

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused peptide drug platform in a specialized, defensible modality with growing validation in biotech
Phase 2 program (Solnatide) in ARDS represents a concrete clinical catalyst in a high-mortality indication
Early-stage structure offers meaningful equity upside and hands-on involvement in drug development

Watch Out For

No revenue, approved products, or public funding disclosures create significant financial visibility risk
Single-digit pipeline (3 trials total) provides limited career optionality if primary program fails
Minimal hiring activity and no disclosed employee count suggest very small team and limited role diversity

Generated by Claude from APEPTICO's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

AP301

Acute Lung Injury

Phase 2

Clinical Trials (1)

NCT01627613Study in Intensive Care Patients to Investigate the Clinical Effect of Repetitive Orally Inhaled Doses of AP301 on Alveolar Liquid Clearance in Acute Lung Injury

Phase 2

Solnatide

ARDS

Phase 2

Clinical Trials (1)

NCT03567577Safety and Preliminary Efficacy of Sequential Multiple Ascending Doses of Solnatide to Treat Pulmonary Permeability Oedema in Patients With Moderate-to-severe ARDS

Phase 2

Open Jobs (0)

No open positions listed yet.

Interview Prep Quick Facts

Portfolio: 3 clinical trials

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo